COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

被引：0
|
作者：
Klijn, S. [1 ]
Van de Wetering, G. [1 ]
Malcolm, B. [2 ]
Dale, P. [2 ]
Pompen, M. [3 ]
Stevanovic, J. [3 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Utrecht, Netherlands
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.272
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN190
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
    Yang, Liu
    Song, Xiaobing
    Zeng, Wanxian
    Zheng, Zhiwei
    Lin, Wenqiang
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [32] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [33] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [34] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [35] A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA
    Lakhdari, K.
    Young, K. C.
    Holdgate, O.
    Doan, J.
    VALUE IN HEALTH, 2018, 21 : S37 - S37
  • [36] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [37] A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
    Reinhorn, Daniel
    Sarfaty, Michal
    Leshno, Moshe
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    ONCOLOGIST, 2019, 24 (03): : 366 - 371
  • [38] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
    Wang, Yufei
    Zhong, Yichen
    Mt-Isa, Shahrul
    Perini, Rodolfo
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
    Ye, Zhuo-miao
    Tang, Zi-Qing
    Xu, Zhe
    Zhou, Qin
    Li, Huan
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345